AVAILABLENCT06931262
Expanded Access Treatment Protocol With DCA for Patients With PDCD
Studying Pyruvate dehydrogenase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Saol Therapeutics Inc
- Principal Investigator
- Kiki Diorgu, M.D.Saol Therapeutics Inc
- Intervention
- Dichloroacetate (DCA)(drug)
- Eligibility
- 0-17 years · All sexes
Collaborators
AnovoRx
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06931262 on ClinicalTrials.govOther trials for Pyruvate dehydrogenase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06887777Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI)Assistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE1NCT06340685Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) DeficiencyJirair Krikor Bedoyan
- ACTIVE NOT RECRUITINGPHASE3NCT02616484Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:Saol Therapeutics Inc
- RECRUITINGNCT03056794Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex DeficienciesUniversity of Pittsburgh